- Hologic Inc (NASDAQ: HOLX) has agreed to acquire Mobidiag Oy, a privately held, Europe-based provider of molecular diagnostic tests and instrumentation, for an enterprise value of approximately $795 million.
- The deal includes a cash payment of approximately $714 million (€600 million) for Mobidiag’s equity and net debt of roughly $81 million.
- Mobidiag develops and markets PCR (polymerase chain reaction)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare-associated infections.
- The Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times ranging from 50 minutes to two hours.
- Mobidiag generated approximately $42 million (€35 million) of revenue in calendar 2020. Hologic intends to invest in assay development to drive the growth of the Novodiag platform.
- The acquisition is roughly $0.10 dilutive to Hologic’s non-GAAP EPS in fiscal 2022, slightly dilutive in 2023, and accretive after that.
- Hologic expects to finance the transaction with cash on hand and borrowing on its existing line of credit.
- The acquisition is expected to close in the fourth quarter of this year.
- The Company ended the December quarter with cash and equivalents of $868.7 million.
- Price Action: HOLX shares are down 0.10% at $72.8 on the last check Thursday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Be First to Comment